All In Biotech

Free tool

FAERS Monitor: Voranigo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218784 or its brand name (Voranigo, Vorasidenib). Reports on generic versions are filed under their own applications.

Reports

612

Serious

463

76% of reports

Hospitalization

135

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • alanine aminotransferase increased83
  • aspartate aminotransferase increased68
  • fatigue67
  • malignant neoplasm progression46
  • seizure41
  • headache39
  • nausea38
  • hepatic cytolysis34
  • hepatic enzyme increased34
  • gamma-glutamyltransferase increased28
  • liver function test increased24
  • hepatotoxicity21
  • drug-induced liver injury20
  • diarrhoea18
  • blood bilirubin increased17

Reports by year received

View as table
YearReports
20232
202442
2025313
2026255

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,547 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic cytolysisSignal3491.966.32,960
alanine aminotransferase increasedSignal8346.538.13,658
aspartate aminotransferase increasedSignal6844.135.22,822
gamma-glutamyltransferase increasedSignal2843.530.31,120
liver function test increasedSignal2438.526.0839
hepatotoxicitySignal2132.421.3609
drug-induced liver injurySignal2021.914.2379
blood bilirubin increasedSignal1721.613.5315
hepatic enzyme increasedSignal3417.112.4502
malignant neoplasm progressionSignal4615.411.7610
seizureSignal4112.29.1413
fatigueSignal673.02.488
headacheSignal392.11.623
nausea381.71.29
diarrhoea181.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.